April 22, 2026 · Form 4 insider transaction
Booth Bruce sold 88 shares of Kymera Therapeutics, Inc. at $90.08 per share, a transaction worth $7.9K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025.; These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of his pecuniary interest therein, if any.